Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment

Pilátová, Kateřina; Bencsiková, Beatrix; Demlová, Regina; Valík, Dalibor; Zdražilová-Dubská, Lenka

doi:10.1007/s00262-018-2166-4

Cited by 14 publications

(19 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MDSCs promote immunosuppression by secreting anti-inflammatory cytokines [21]. IL-10, which is produced by the MDSCs, arrests the production of interferon-γ (IFN-γ) by CD4 + T cells, along with promoting the metastasis of cancer cells [2,19,24]. The production of IL-10 is further upregulated by HMGB1 [24,47].…”

Section: Anti-inflammatory Cytokine Production Exosomes and Immune mentioning

confidence: 99%

“…M-MDSCs were established as CD14 + CD15 − CD11b + CD33 + HLA-DR − Lin − , as well as CD14 + CD15 + CD11b + CD33 + HLA-DR − Lin − , whereas the PMN-MDSC subpopulation was designated as CD14 − CD15 + CD11b + CD33 + HLA-DR − Lin − or CD11b + CD14 − CD66b + [13][14][15]. Recently, another MDSC subtype was proposed, called early-stage MDSC (eMDSC), which lucks the markers for both monocytic and granulocytic populations, baring the phenotype of Lin − HLA-DR − CD33 + CD11b + CD14 − CD15 − [13,[15][16][17][18][19]. These cell populations not only exist as free cells in the peripheral blood, but also as enriched cell populations in the tumor microenvironment (TME) [20].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer

Vetsika

Koukos

Κotsakis

2019

Cells

View full text Add to dashboard Cite

Myeloid-derived suppressor cells (MDSCs) constitute a vast population of immature myeloid cells implicated in various conditions. Most notably, their role in cancer is of great complexity. They exert immunosuppressive functions like hampering cancer immunity mediated by T lymphocytes and natural killer cells, while simultaneously they can recruit T regulatory cells to further promote immunosuppression, thus shielding tumor cells against the immune defenses. In addition, they were shown to support tumor invasion and metastasis by inducing vascularization. Yet again, in order to exert their angiogenic activities, they do have at their disposal a variety of occasionally overlapping mechanisms, mainly driven by VEGF/JAK/STAT signaling. In this concept, they have risen to be a rather attractive target for therapies, including depletion or maturation, so as to overcome cancer immunity and suppress angiogenic activity. Even though, many studies have been conducted to better understand these cells, there is much to be done yet. This article hopes to shed some light on the paradoxal complexity of these cells, while elucidating some of the key features of MDSCs in relation to immunosuppression and, most importantly, to the vascularization processes, along with current therapeutic options in cancer, in relation to MDSC depletion.

show abstract

Section: Anti-inflammatory Cytokine Production Exosomes and Immune mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer

Vetsika

Koukos

Κotsakis

2019

Cells

View full text Add to dashboard Cite

show abstract

“…Cancer development is caused by accumulation of intrinsic cellular changes that are shaped by host-related factors such as inflammatory cells and cytokine/ chemokine levels in the tumor macro and microenvironment. Chronic inflammation supports cancer angiogenesis, glycolytic phenotype and Th2 immune response and thus contributes to cancer progression [1,2].…”

Section: Introductionmentioning

confidence: 99%

“…Majority of published studies focuses on M-MDSCs or total MDSCs. Granulocytic fraction of MDSCs can be defined as low density immature myeloid PMN-MDSCs or CD33 hi mature presumably activated PMN-MDSCs [1].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer – Exploratory Analysis of Their Biomarker Potential

Fědorová

Pilátová²,

Selingerová³

et al. 2018

Klin Onkol

View full text Add to dashboard Cite

Background: Myeloid-derived suppressor cells (MDSCs) contribute to tumor escape from host immune surveillance and to tumor progression by producing tumor-promoting factors. We focused on clinical and analytical MDSCs-related issues as potential bio markers and immune regulators involved in tumor progression. Patients and Methods: We analyzed 10 patients with advanced colorectal carcinoma (CRC) with (M1 subgroup) or without (M0 subgroup) distant metastases at dia gnosis. Peripheral blood was collected at dia gnosis prior to treatment and subsequently 12 months after therapy initiation. Using multicolor flow cytometry MDSC subsets were evaluated. Monocytic MDSCs (M-MDSCs) were detected as CD45 + CD11b + CD33 + HLA-DR low/ − CD14 + CD15-, granulocytic MDSCs (CD33 hi PMN-MDSC) were detected as CD45 + CD11b + CD33 hi HLA-DR low/ − CD14 − CD15 +. For analytical and preanalytical studies, random fresh blood specimens predominantly from cancer patients were analyzed. Results: Levels of circulating M-MDSCs were not associated with metastatic disease within advanced CRC patients. Levels of circulating CD33 hi PMN-MDSCs were elevated in patients with distant metastases compared to T3 M0 subgroup. Circulating M-MDSCs increased upon treatment initiation in 9 out of 10 patients. CD33 hi PMN-MDSCs substantially dropped upon treatment initiation in 5 out of 10 patients and substantially increased in 2 out of 10 patients. Analytical part showed that absolute and relative counts within each MDSC subset are correlated. Coefficient of variation (CV) for repeatability was 6-11% for M-MDSCs and 25-44% for CD33 hi PMN-MDSCs. CV for reproducibility was higher with 8-22% for M-MDSCs and 35-79% for CD33 hi PMN-MDSCs demonstrating that delay in measurement of MDSCs in whole blood specimen may distort quantification of circulating MDSC subsets. Conclusion: The quantification of MDSC subsets is substantially dependent on the type of specimen examined and its preanalytical processing. Exploratory analysis of M-MDSCs and CD33 hi PMN-MDSCs in CRC patients revealed different dynamics of M-MDSC and CD33 hi PMN-MDSC subsets in the context anti-cancer treatment.

show abstract

Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancer

Tsukazaki,

Ogino,

Okano

et al. 2024

Int J Clin Oncol

View full text Add to dashboard Cite

Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment

Cited by 14 publications

References 58 publications

Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer

Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer

Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer – Exploratory Analysis of Their Biomarker Potential

Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancer

Contact Info

Product

Resources

About